Biopharmaceutical company Immatics said Tuesday it will combine with blank check company Arya Sciences to create a publicly traded company with an expected market capitalization of roughly $634 million, in a deal steered by a Goodwin team including Jocelyn Arel, Mitch Bloom and Michael Patrone. Michael Patrone, a partner in the firm’s M&A/Corporate Governance practice and Life Sciences group, said SPAC transactions provide additional flexibility during the go-public process. Read the Law360 article here.